A filing with the Securities and Exchange Commission shows the company is seeking $2 million in total investment. Funds raised will serve as working capital for product development and “other general corporate purposes.” Some of the proceeds may go toward paying executive officers as well.

The company is still pre-revenue, the filing shows.

For this round, the minimum investment accepted is $10,000.

Dianomi is led by CEO and co-founder Barry Kurokawa, who’s been a life sciences investor for more than two decades. Near the end of 2018, the company moved into the recently created Forward BIOLABS.

The company is developing an array of treatments, first targeting several types of arthritis.

See the SEC form: http://www.sec.gov/Archives/edgar/data/1737087/000173708719000002/xslFormDX01/primary_doc.xml